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Abstract
AIM
To investigate the usefulness of aspartate amino-
transferase to platelet ratio index (APRI) in predicting 
hepatocellular carcinoma (HCC) risk in primary biliary 
cholangitis (PBC).
METHODS
We identified PBC patients between 2000 and 2015 by 
searching the electronic medical database of a tertiary 
center. The hazard ratio (HR) of HCC with different risk 
factors was determined by Cox proportional hazards 
model. 
RESULTS
One hundred and forty-four PBC patients were recru-
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ited. Patients were diagnosed at a median age of 57.8 
years [interquartile range (IQR): 48.7-71.5 years), 
and 41 (28.5%) patients had cirrhosis at baseline. 
The median follow-up duration was 6.9 years (range: 
1.0-26.3 years). Twelve patients developed HCC, with 
an incidence rate of 10.6 cases per 1000 patient-years. 
The overall 5-, 10- and 15-year cumulative incidences 
of HCC were 2.3% 95%CI: 0%-4.8%), 8.4% (95%CI: 
1.8%-14.5%) and 21.6% (6.8%-34.1%), respectively. 
Older age (HR = 1.07), cirrhosis (HR = 4.38) and 
APRI at 1 year after treatment (APRI-r1) > 0.54 (HR = 
3.94) were independent factors for HCC development. 
APRI-r1, when combined with treatment response, 
further stratified HCC risk (log rank P  < 0.05). The area 
under receiver operating curve of APRI-r1 in predicting 
HCC was 0.77 (95%CI: 0.64-0.88).
CONCLUSION
APRI-r1 can be used to predict the development of HCC 
in PBC patients. Combination of APRI-r1 with treatment 
response can further stratify the HCC risk.
Key words:  Aspartate aminotransferase; Platelet 
ratio index; Hepatocellular carcinoma; Primary biliary 
cholangitis; Ursodeoxycholic acid; Cirrhosis
© The Author(s) 2017. Published by Baishideng 
Publishing Group Inc. All rights reserved.
Core tip: Currently, no reliable predictive models 
exist for hepatocellular carcinoma (HCC) in primary 
biliary cholangitis (PBC). Our study showed that a 
higher aspartate aminotransferase to platelet ratio 
index (APRI) at 1 year after treatment (APRI-r1) was 
associated with a higher HCC risk. The performance 
of APRI-r1 in predicting HCC was satisfactory (area 
under the receiver operating curve: 0.77). Combination 
of APRI-r1 with treatment response further stratified 
HCC risk. Owing to its simplicity, non-invasiveness 
and cost-effectiveness, APRI can be used as a marker 
to streamline the HCC surveillance protocol in PBC 
patients.
Cheung KS, Seto WK, Fung J, Mak LY, Lai CL, Yuen MF. 
Prediction of hepatocellular carcinoma development by 
aminotransferase to platelet ratio index in primary biliary 
cholangitis. World J Gastroenterol 2017; 23(44): 7863-7874 
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INTRODUCTION
Primary biliary cholangitis (PBC) is an immune-
mediated, chronic cholestatic liver disease due to the 
destruction of small-sized biliary ducts with progressive 
liver fibrosis[1]. The disease prevalence ranges from 
19 to 402 per million[2] and 48 to 56 per million[3,4] in 
the western and Asian populations, respectively. If left 
untreated, patients will develop portal hypertension, 
cirrhosis and hepatocellular carcinoma (HCC) with 
resulting mortality[5].
Ursodeoxycholic acid (UDCA) is recommended in 
all PBC patients to delay histologic progression, reduce 
cirrhotic complications, and improve the long-term 
survival[6-9]. Recently, suboptimal treatment response 
to UDCA is recognized to be a risk factor for HCC 
development[10]. Various biochemical response criteria 
have been developed and validated, which include 
the Rotterdam criteria[11], Paris I criteria[12], Paris Ⅱ 
criteria[13], Barcelona criteria[7], and Toronto criteria[14].
In addition, the HCC risk was significantly 
increased in patients with significant fibrosis and 
cirrhosis. Traditionally, liver biopsy is regarded as 
the gold standard diagnostic method, but it may 
not be desirable in daily clinical practice due to its 
associated invasiveness which may lead to various 
complications[15]. Aspartate aminotransferase (AST) to 
platelet ratio index (APRI) is a serum marker shown 
to be able to assess liver fibrosis and cirrhosis across 
a wide array of chronic hepatic diseases[16-22]. It has 
the advantage of being easily calculated from routine 
laboratory results. Studies suggested that it could 
predict HCC risk in chronic hepatitis B (CHB)[23] and 
C (CHC) infection[24] and had prognostic value in 
CHB patients who underwent surgery for early stage 
HCC[25]. 
Recently, APRI is also found to be a prognostic 
marker in PBC patients independent of UDCA 
response[26]. This is attributed to its ability to 
not only capture fibrosis/cirrhosis, but also to 
reflect other biologically significant pathways like 
hepatic necroinflammation or non-cirrhotic portal 
hypertension[26-28]. Both APRI at baseline and APRI at 
1 year after treatment (APRI-r1) have been shown 
to predict adverse outcomes (liver transplantation 
and/or death) in PBC patients[26]. In addition, when 
combined with the treatment response criteria, APRI-r1 
can further stratify the risk of adverse outcomes and 
improve the predictive performances[26,29]. 
However, whether APRI can predict HCC risk in PBC 
patients remains uncertain. We aimed to demonstrate 
the role of APRI, alone and in combination with 
treatment response, in predicting HCC development in 
PBC patients receiving UDCA. 
MATERIALS AND METHODS
Study subjects
PBC patients who followed up at the Clinic of He-
patology Unit of Queen Mary Hospital (QMH), a tertiary 
referral center, between January 2000 and October 
2015 were recruited. 
As all patients with PBC were prescribed with UDCA 
in QMH, we first identified patients receiving UDCA 
between 2000 and 2015 by searching the electronic 
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medical database of QMH. Subsequently, we excluded 
non-PBC cases by reviewing the patient records, based 
on the criteria described in the subsequent section. 
Other exclusion criteria included non-Chinese et-
hnicity, cases with UDCA prescription for less than 
1 year, overlap syndrome[30] and other coexisting 
hepatic diseases including CHB and CHC infection, 
steatohepatitis, alcoholic liver disease, and Wilson’s 
disease. Figure 1 illustrates the patient recruitment 
process.
Ethics approval was issued by the Institutional 
Review Board, The University of Hong Kong and West 
Cluster of Hospital Authority, Hong Kong.
Diagnosis of PBC
A diagnosis of PBC was made if two out of the fo-
llowing three criteria were fulfilled: (1) cholestatic 
liver function pattern with raised alkaline phosphatase 
(ALP) ≥ 1.5 times the upper limit of normal (ULN); (2) 
presence of anti-mitochondrial antibody (AMA); and (3) 
liver biopsy showing the histology of “nonsuppurative 
destructive cholangitis with destruction of interlobular 
biliary ducts”[5]. For liver biopsy cases, histologic staging 
was reported in accordance with Ludwig et al[31].
The Paris Ⅱ criteria were proposed by Corpechot 
et al[13] for predicting adverse events in PBC patients 
with early-stage disease. Early PBC can be defined 
either histologically (Ludwig’s stages Ⅰ and Ⅱ) or 
biochemically (normal levels of albumin and bilirubin).
Diagnosis of adverse events
Patients had regular follow-up every 3 to 6 mo 
to monitor the platelet count, liver biochemistry, 
prothrombin time (PT) and alpha-fetoprotein level. 
Patients were recommended for ultrasonography (USG) 
of the liver every 6 mo for HCC[32].
A diagnosis of HCC was made by histology and/
or imaging features [i.e. arterial enhancement and 
venous wash-out on triphasic computed tomography 
(CT) scan or magnetic resonance imaging (MRI)].
A diagnosis of cirrhosis was made by any one 
of the following: (1) imaging (USG, CT or MRI) 
showing small liver with surface nodularity, or signs 
of portal hypertension (including splenomegaly, 
ascites and varices); (2) fibrosis score > 16.9 kPa on 
transient elastography[33]; and (3) clinical features 
including thrombocytopenia, prolonged prothrombin 
time, ascites, varices, hepatic encephalopathy and 
hepatorenal syndrome. 
APRI was calculated by the following formula 
proposed by Wai et al[16]: [(AST value/ULN)/platelet 
count (109/L)] × 100.
Suboptimal treatment response to UDCA
For the initial analysis, we used the Rotterdam 
criteria (abnormal levels of bilirubin or albumin) 
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Figure 1  Flowchart illustrating case search and identification process. HBV: Hepatitis B virus; PBC: Primary biliary cholangitis; UDCA: Ursodeoxycholic acid. 
Patients prescribed with UDCA between January 
2000 and October 2015 (n  = 264)
n  = 195
n  = 186
n  = 178
n  = 144
non-PBC (n  = 69)
non-Chinese (n  = 9)
Concomitant liver diseases (n  = 8)
     HBV infection (n  = 4)
     overlap syndrome (n  = 4)
baseline blood tests unavailable (n  = 21)
unknown UDCA commencement date (n  = 2)
intolerant to UDCA (n  = 2)
received UDCA < 1 yr (n  = 2)
died within 1 yr of UDCA (n  = 7)
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underwent liver transplantations, and there were 40 
deaths (21 were liver-related and 19 were non-liver-
related). 
Cirrhosis was noted in 41 patients (28.5%) before 
treatment commencement, while the median APRI and 
APRI-r1 levels of the cohort were 1.00 (0.60 to 1.84) 
and 0.22 (0.13 to 0.43), respectively. A significantly 
higher proportion of patients who developed HCC had 
baseline cirrhosis compared with the non-HCC group 
(66.7% vs 25.0%, p = 0.005). The HCC group also 
had a higher median APRI-r1 level (0.54 vs 0.20, p 
= 0.002), with a larger proportion having APRI-r1 > 
0.54 (50.0% vs 16.7%, p = 0.013). The difference in 
median APRI levels between the two groups was of 
borderline significance (2.02 vs 0.97, p = 0.050), while 
no significant difference existed for the proportions 
of patients with APRI > 0.54 (90.0% vs 77.5%, p = 
0.689). For other prognostic scores, the HCC group 
had a higher median Mayo risk score (5.1 vs 4.6, p 
= 0.022), while no significant differences existed for 
the model for end-stage liver disease (MELD) or Child-
Pugh (CP) scores between the two groups. 
Patients were prescribed with UDCA at a median 
dose of 750 mg. The number of patients who had 
suboptimal treatment response was as follows: 
61 (42.4%; Rotterdam criteria), 52 (36.1%; Paris 
Ⅰ criteria), 48 (33.3%; Barcelona criteria) and 50 
(38.8%; Toronto criteria). None of our patients 
received fibric acid derivatives.
Liver biopsies were performed in 62 patients. Out 
of the 52 patients with histology reports available, 21 
were regarded as having early-stage PBC. If only the 
biochemical criteria were considered, 52 patients had 
early-stage disease. None of these patients developed 
HCC, and therefore analysis could not be performed 
using the Paris Ⅱ criteria. 
Correlation between baseline APRI and other variables
APRI had positive correlations with levels of AST (r = 
0.86, p < 0.001), ALT (r = 0.68, p < 0.001), bilirubin 
to define suboptimal treatment response. This is 
because the Rotterdam criteria were shown to have 
better predictive performances than other treatment 
response criteria in predicting requirement for liver 
transplantation and death in Chinese PBC patients[34,35]. 
Analyses by using other treatment response criteria 
were also performed. Table 1 illustrates the description 
of other prognostic models[26]. Combination of APRI-r1 
with treatment response could further stratify PBC 
patients into low-risk (APRI-r1 ≤ 0.54 with treatment 
response), intermediate-risk (APRI-r1 ≤ 0.54 with 
suboptimal treatment response, or APRI-r1 > 0.54 
with treatment response) and high-risk (APRI-r1 > 
0.54 with suboptimal treatment response) groups 
of developing adverse events in terms of liver 
transplantation or death. 
Statistical analysis 
Statistical analyses were performed using R version 
3.2.3 (R Foundation for Statistical Computing) sta-
tistical software. We expressed continuous variables 
in terms of median and interquartile range (IQR). The 
correlation between continuous variables was assessed 
by Spearman’s bivariate correlation. We used Mann-
Whitney U-test to assess the difference in continuous 
variables of two groups. We used χ 2 test or Fisher’s 
exact test for the comparison of categorical variables. 
The hazard ratio (HR) of HCC with different variables 
was derived from the Cox proportional hazards model. 
Patients not meeting the clinical endpoint (HCC) were 
censored at latest follow-up or death. The follow-up 
duration was calculated from the date of diagnosis 
to the censored date. Missing data in the Cox model 
were handled by multiple imputation, wherein 50 
complete datasets were constructed by imputing 
the missing values[36]. The development of HCC was 
analyzed by the Kaplan-Meier method, and statistical 
significance was determined by the log-rank test. By 
plotting “sensitivity” against “1-specificity”, the receiver 
operating curve was generated. The performances of 
different models were expressed by area under the 
receiver operating curve (AUROC), with the 95% CI 
being deduced from bootstrapping by sampling with 
replacement from the original dataset and repeating 
the process by 1000 times. A two-sided p-value of < 
0.05 was used to define statistical significance. 
RESULTS 
Characteristics of study patients
One hundred and forty-four PBC patients were 
recruited, and 127 were female (88.2%). Table 2 
shows the patient characteristics, laboratory and 
histology results. Patients were diagnosed at a median 
age of 57.8 years (IQR: 48.7 to 71.5 years). The 
median follow-up duration was 6.9 years (range: 1.0 
to 26.3 years), making a total of 1136 patient-years. 
Twelve patients developed HCC, with an incidence rate 
of 10.6 cases per 1000 patient-years. Ten patients 
Table 1  Descriptions of prognostic risk models for primary 
biliary cholangitis
Time of 
evaluation
Definition of suboptimal treatment 
response
Rotterdam 1 yr Abnormal bilirubin and/or albumin
Paris Ⅰ 1 yr ALP ≥ 3 × ULN or AST ≥ 2 × ULN 
or bilirubin > 1 mg/dL
Paris Ⅱ 1 yr ALP > 1.5 × ULN or AST > 1.5 × ULN 
or bilirubin > 1 mg/dL
Barcelona 1 yr ALP > 1 × ULN and decrease in ALP < 
40%
Toronto 2 yr ALP > 1.67 × ULN
APRI Baseline AST/ULN of AST/platelet (× 109) × 100
APRI-r1 1 yr AST/ULN of AST/platelet (× 109) × 100
ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; APRI: 
AST to platelet ratio index; APRI-r1: APRI at 1-year; AST: Aspartate 
aminotransferase; PBC: Primary biliary cholangitis; ULN: Upper limit of 
normal.
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Figure 2  Cumulative hepatocellular carcinoma incidence. A: Whole cohort; B: Stratified by APRI-r1. APRI-r1: AST/platelet ratio index at 1-year.
Table 2  Baseline characteristics of the study cohort 
Variable Whole cohort,
n  = 144
Patients with HCC, 
n  = 12
Patients without HCC, 
n  = 132
P value
Age, yr 57.8 (48.7-71.5) 68.1 (56.2-74.6) 57.0 (48.2-70.7) 0.278
Female sex 127 (88.2) 9 (75.0) 118 (89.4) 0.153
Duration of follow-up, yr 6.9 (3.5-10.4) 8.9 (5.2-11.4) 6.8 (3.5-10.1) 0.499
Ursodeoxycholic acid, mg 750 (750-750) 750 (750-750) 750 (750-750) 0.576
Suboptimal treatment response, 61 (42.4) 9 (75.0) 52 (39.4) 0.0173
Rotterdam criteria
Diabetes 29 (20.1) 6 (50.0) 23 (17.4) 0.0163
Smoking1 13 (9.5) 4 (33.3) 9 (6.8) 0.0113
Alcohol1 17 (13.7) 2 (16.7) 15 (11.4) 0.623
Cirrhosis 41 (28.5) 8 (66.7) 33 (25.0) 0.0053
Histological stage 3-42 23 (44.2) 3 (50.0) 20 (43.5) 1.00
Platelet, x 109/L1 216 (152-262) 133 (95-150) 229 (175-266) < 0.0013
Creatinine, μmol/L1 69 (60-82) 73 (60-79) 68 (60 - 82) 0.0473
Albumin, g/L1 40 (36-42) 24 (14-30) 40 (36-42) 0.087
Bilirubin, μmol/L1 14 (10-26) 30 (19-55) 14 (10-26) < 0.0013
ALP (U/L) 284 (196-484) 343 (227-362) 273 (196-496) 0.991
ALT, U/L1 74 (54-130) 85 (64-109) 74 (53-133) 0.565
AST, U/L1 68 (51-115) 76 (56-109) 68 (51-115) 0.741
GGT, U/L1 517 (256-771) 626 (353-843) 490 (224-760) 0.285
PT, s 11.3 (10.5-11.7) 11.8 (11.7-12.5) 11.2 (10.5-11.7) 0.0073
AMA positivity 119 (82.6) 8 (66.7) 111 (84.1) 0.223
Globulin, mg/dL1 41 (37-46) 40 (37-44) 41 (37-46) 0.337
IgM, mg/dL1 363 (250-502) 446 (282-579) 359 (250-478) 0.563
Mayo risk score1 4.7 (3.8-5.5) 5.1 (4.8-6.6) 4.6 (3.8-5.4) 0.0223
MELD score 6 (6-8) 8 (6-9) 6 (6-7) 0.097
CP score1 5 (5-6) 6 (5-6) 5 (5-6) 0.125
CP class B/C1 29 (20.1) 2 (16.7) 25 (19.2) 1.00
APRI 1.00 (0.60-1.84) 2.02 (1.05-3.34) 0.97 (0.59-1.72) 0.053
APRI > 0.541 102 (78.5) 9 (90.0) 93 (77.5) 0.689
APRI-r11 0.22 (0.13-0.43) 0.54 (0.31-0.70) 0.20 (0.13-0.38) 0.0023
APRI-r1> 0.541 27 (19.6) 6 (50.0) 21 (16.7) 0.0133
Data are presented as n (%), and all continuous variables are expressed as median (interquartile range). 1Missing data: smoking (7), alcohol (3), platelet (10), 
creatinine (1), albumin (2), bilirubin (2), ALT (2), AST (6), GGT (2), globulin (6), IgM (20), Mayo risk score (2), CP score (2), APRI (14), APRI-r1 (6); 2Sixty-
two patients had liver biopsies done, with reports available for review for 52; 3P values < 0.05. All continuous variables expressed in median (interquartile 
range). ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AMA: Anti-mitochondrial antibody; APRI: AST/platelet ratio index; APRI-r1: APRI at 
1 year after treatment; AST: Aspartate aminotransferase; CP: Child-Pugh; GGT: Gamma-glutamyl transferase; IgM: Immunoglobulin M; MELD: Model for 
end-stage liver disease; PT: Prothrombin time.
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(r = 0.43, p < 0.001), ALP (r = 0.31, p < 0.001) 
and gamma-glutamyl transferase (GGT) (r = 0.31, 
p < 0.001). It had negative correlations with platelet 
counts (r = -0.43, p < 0.001) and albumin levels (r = 
-0.27, p = 0.002). The correlation between APRI and 
PT was of borderline significance (r = 0.17, p = 0.052). 
For the correlations with other prognostic models, 
there were positive correlations between APRI and 
Mayo risk score (r = 0.32, p < 0.001) and CP score (r 
= 0.43, p < 0.001), but not for the MELD score (r = 
0.12, p = 0.664). 
HCC risk factors
Table 3 shows the association between HCC de-
velopment and various factors. On univariate analysis, 
significant factors for HCC development included older 
age, male sex, presence of cirrhosis, hypoalbuminemia 
and suboptimal treatment response (defined by the 
Rotterdam criteria). On multivariate analysis, only older 
age (HR = 1.07; 95%CI: 1.02-1.12), cirrhosis (HR = 
4.38; 95%CI: 1.06-18.14) and APRI-r1 > 0.54 (HR 
= 3.94; 95%CI: 1.04-14.94) were independent risk 
factors (Table 4). Suboptimal treatment response was 
Cheung KS et  al.  APRI predicts HCC risk in PBC
Figure 3 Cumulative hepatocellular carcinoma incidence stratified by treatment response. A: Rotterdam criteria; B: Paris I criteria; C: Barcelona criteria; D: 
Toronto criteria.
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not a significant independent risk factor irrespective of 
which treatment response criteria being used. 
Patients were further stratified into low-, inter-
mediate- and high-risk groups. High-risk patients 
(APRI-r1 > 0.54 with suboptimal biochemical response) 
had the highest risk of developing HCC, with consistent 
results for the Rotterdam, Paris Ⅰ and Barcelona criteria, 
while the difference was of borderline significance 
using the Toronto criteria (Table 5).
HCC cumulative incidence 
The 5-, 10- and 15-year cumulative incidences of 
HCC were 2.3% (95%CI: 0%-4.8%), 8.4% (95%CI: 
1.8%-14.5%) and 21.6% (6.8%-34.1%), respectively 
(Figure 2A). 
Cumulative incidence of HCC was significantly 
higher for patients with APRI-r1 > 0.54 (log rank p = 
0.002; Figure 2B). Among patients with APRI-r1 ≤
0.54, the 5-, 10- and 15-year cumulative incidences 
of HCC were 2.5%(95%CI: 0%-3.0%), 6.7%(95%CI: 
0%-13.1%) and 18.3% (95%CI: 0.4%-33.0%), 
respectively. Among patients with APRI > 0.54, the 
5-, 10- and 15-year cumulative incidences of HCC 
development were 8.3% (95%CI: 0%-18.7%), 
18.5% (95%CI: 0%-37.2%) and 49.0% (95%CI: 
0%-75.2%).
Cumulative incidence of HCC was significantly 
higher for patients who had suboptimal biochemical 
response by using the Rotterdam (log rank p = 0.003) 
and Paris I criteria (log rank p = 0.038). The difference 
was of borderline significance by using the Barcelona 
criteria (log rank p = 0.061), while there was no 
significant difference by using the Toronto criteria (log 
Table 3  HRs and 95%CIs for the association between hepatocellular carcinoma development and different variables
Variables Univariate analysis Multivariate analysis
HR 95%CI P  value HR 95%CI P  value
Age, yr 1.06 1.01-1.11 0.0162 1.07 1.02-1.12 0.0042
Male sex 5.22 1.27-21.44 0.0222 3.67 0.69-19.56 0.128
Diabetes mellitus 3.01 0.96-9.44 0.058
Cirrhosis 8.02 2.35-27.29 < 0.0012 4.38 1.06-18.14 0.0412
APRI > 0.54 3.43 0.43-27.19 0.243
APRI-r1 > 0.54 5.10 1.64-15.86 0.0052 3.94 1.04-14.94 0.0432
Creatinine, μmol/L 1.02 0.99-1.05 0.222
Albumin, g/L 0.85 0.75-0.96 0.0072
Bilirubin, µmol/L 1.01 0.98-1.03 0.514
ALP, U/L 0.997 0.994-1.00 0.104
ALT, U/L 0.996 0.987-1.00 0.331
AST, U/L 0.996 0.975-1.01 0.467
GGT, U/L 1.00 0.999-1.001 0.975
PT, s 1.40 0.99-1.98 0.0602
AMA positivity 0.52 0.16-1.75 0.292
Globulin, mg/dL 0.99 0.90-1.08 0.804
IgM, mg/dL 1.00 0.997-1.002 0.830
Suboptimal treatment response, Rotterdam criteria1 5.95 1.59-22.26 0.0082 2.18 0.45-10.58 0.334
1In the multivariate analyses, albumin was not included as this variable was already included in the Rotterdam criteria. 2P values < 0.05. ALP: Alkaline 
phosphatase; ALT: Alanine aminotransferase; AMA: Anti-mitochondrial antibody; APRI: AST to platelet ratio index; APRI-r1: APRI at 1 year after 
treatment; AST: Aspartate aminotransferase; CI: Confidence interval; GGT: Gamma-glutamyl transferase; HR: Hazard ratio; IgM: Immunoglobulin M; PT: 
Prothrombin time.
Table 4  Adjusted HRs and 95%CIs for the association 
between hepatocellular carcinoma development and different 
variables 
Criteria HR 95%CI P  value
Rotterdam 
   Age 1.07 1.02-1.12 0.0041
   Male sex 3.67 0.69-19.56 0.128
   Cirrhosis 4.38 1.06-18.14 0.0411
   APRI-r1 > 0.54 3.94 1.04-14.94 0.0431
   Suboptimal treatment response 2.18 0.45-10.58 0.334
Paris Ⅰ 
   Age 1.07 1.02-1.12 0.0031
   Male sex 3.04 0.54-17.12 0.207
   Albumin 0.94 0.80-1.09 0.386
  Cirrhosis 4.37 1.07-17.75 0.0391
   APRI-r1 > 0.54 3.92 1.06-14.54 0.0411
   Suboptimal treatment response 1.7 0.41-7.03 0.466
Barcelona 
   Age 1.07 1.02-1.12 0.0051
   Male sex 3.26 0.56-18.96 0.188
   Albumin 0.93 0.80-1.07 0.307
   Cirrhosis 4.44 1.06-18.56 0.0411
   APRI-r1 > 0.54 4.47 1.26-15.93 0.0211
   Suboptimal treatment response 1.22 0.33-4.49 0.768
Toronto 
  Age 1.07 1.02-1.13 0.0031
  Male sex 3.22 0.56-18.50 0.19
   Albumin 0.94 0.80-1.09 0.425
  Cirrhosis 4.56 1.09-19.17 0.0381
   APRI-r1 > 0.54 4.16 1.10-15.69 0.0361
   Suboptimal treatment response 1.46 0.31-6.89 0.631
1P-values < 0.05. The adjusted HR for suboptimal response was derived 
by multivariate analysis with other significant variables in Table 3 (age, 
male sex, cirrhosis and albumin) included. Separate multivariate analysis 
was performed for each criteria in defining suboptimal response. In 
the multivariate analyses, albumin was not included for the Rotterdam 
criteria. APRI-r1: AST/platelet ratio index at 1-year; HR: Hazard ratio.
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rank p = 0.370) (Figure 3A-D).
Using the combination of APRI-r1 and biochemical 
response to define low-, intermediate- and high-risk 
groups further stratified HCC risk (all log rank p < 0.05), 
with the exception for the Toronto criteria (log rank p 
= 0.120) (Figure 4A-D). When APRI-r1 was combined 
with treatment response as defined by the Rotterdam 
criteria, the 5-, 10- and 15-year cumulative incidences 
of HCC were 0%, 4.3% (95%CI: 0%-10.0%) and 
10.3% (95%CI: 0%-22.0%), respectively among 
the low-risk group. For the intermediate-risk group, 
the 5-year, 10- and 15-year cumulative incidences of 
HCC were 2.7% (95%CI: 0%-7.8%), 11.5% (95%CI: 
0%-27.2%) and 33.7% (95%CI: 0%-63.5%), 
respectively. The high-risk group was at the highest 
risk, with the 5-, 10- and 15-year cumulative in-
cidences of HCC being 10.2% (95%CI: 0%-22.7%), 
21.4% (95%CI: 0%-41.9%) and 58.1% (95%CI: 
0%-84.0%), respectively.
Predictive performances of various prognostic models
Table 6 shows the predictive performances of various 
prognostic models. APRI-r1 had the best performance 
in predicting HCC development (AUROC = 0.77, 
95%CI: 0.64-0.88), although the 95%CI overlapped 
with that of Mayo risk score (AUROC = 0.70, 95%CI: 
0.54-0.84), cirrhosis (AUROC = 0.71, 95%CI: 
0.56-0.86) and thrombocytopenia (< 150 × 109/L) 
(AUROC = 0.75, 95%CI: 0.58-0.90). APRI, MELD CP 
scores and hyperbilirubinemia (> 17 μmol/L) did not 
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Figure 4  Kaplan-Meier survival plot stratified by APRI-r1 and treatment response. A: Rotterdam criteria; B: Paris I criteria; C: Barcelona criteria; D: Toronto 
criteria. APRI-r1: AST/platelet ratio index at 1-year; low-risk (biochemical response with APRI-r1 ≤ 0.54), intermediate risk (suboptimal biochemical response with 
APRI-r1 ≤ 0.54, or biochemical response with APRI-r1 > 0.54) and high risk (suboptimal biochemical response with APRI-r1 > 0.54).
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have satisfactory performances, as the AUROCs were 
less than 0.70, with the 95%CI crossing 0.50. 
The performances of various treatment response 
criteria were also unsatisfactory (all AUROCs less than 
0.70), with the Rotterdam and Paris I criteria showing 
comparable AUROCs (around 0.68), while the 95%CI 
of the AUROCs of the Barcelona and Toronto criteria 
crossed 0.50. The Rotterdam criteria had the highest 
sensitivity and negative predictive value. 
DISCUSSION
In the current study, a total of 144 Chinese PBC 
patients with UDCA use were recruited. A study with 
the same cohort of patients assessed by different 
prognostic models for prediction of long-term 
transplant-free survival was recently published[34]. 
Our patients were diagnosed at a slightly older age 
than that reported in the West (median: 57.8 vs 54.5 
years)[37]. The female preponderance (88% of our 
cohort) and the treatment response (33%-42%) were 
consistent with those reported in the West[5,12]. 
APRI is widely used in the assessment of fibrosis/
cirrhosis in various kinds of hepatic diseases (CHB and 
CHC infection, alcoholic liver disease and non-alcoholic 
fatty liver disease)[16-22]. A recent study proposed that 
APRI could be used to predict adverse outcomes in 
PBC patients[26]. However, its potential role in HCC 
prediction in PBC patients is still not clear. A meta-
analysis reports an 18.8-fold increase of HCC risk in 
PBC patients compared with the general population[38], 
but it suggests that HCC may not be as common in 
PBC patients compared with other liver diseases[39]. 
Therefore, a non-invasive test that is simple and cost-
Table 5  Prediction of hepatocellular carcinoma development by APRI-r1 in combination with suboptimal treatment response 
Criteria Univariate analysis Multivariate analysis1
HR 95%CI P  value P  trend HR 95%CI P  value P  trend
Rotterdam
   Low-risk Ref - - Ref - -
   Intermediate-risk 2.81 0.56-14.01 0.208 < 0.0012 1.54 0.25-9.63 0.644 0.0062
   High-risk 10.29 2.55-41.48 0.0012 7.95 1.56-40.45 0.0122
Paris I
   Low-risk Ref - - Ref - -
   Intermediate-risk 2.81 0.63-12.60 0.177 0.0032 2.34 0.40-13.60 0.345 0.0132
   High-risk 8.38 1.99-35.21 0.004 7.28 1.45-36.71 0.0162
Barcelona
   Low-risk Ref - - Ref - -
   Intermediate-risk 1.28 0.29-5.72 0.75 0.0022 0.53 0.08-3.34 0.496 0.0382
   High-risk 10.66 2.85-39.89 < 0.0012 5.54 1.29-23.71 0.0212
Toronto
   Low-risk Ref - - Ref - -
   Intermediate-risk 3.25 0.81-13.06 0.097 0.052 4.4 0.97-19.90 0.055 0.061
   High-risk 4.22 0.85-20.97 0.079 4.77 0.78-29.24 0.091
1The adjusted HR for suboptimal response was derived by multivariate analysis with other significant variables in Table 3 (age, male sex, cirrhosis and 
albumin) included; 2P-values < 0.05. Separate multivariate analysis was performed for each criteria in defining suboptimal response. In the multivariate 
analyses, albumin was not included for the Rotterdam criteria, as this variable was already included in the criteria. APRI-r1: AST/platelet ratio index at 
1-year; CI: Confidence interval; HR: Hazard ratio.
Table 6  Predictive performances of prognostic models for hepatocellular carcinoma development 
Categorical variable Rotterdam Paris I Barcelona Toronto Cirrhosis Thrombocytopenia,  
< 150 × 109/L
Hyperbilirubinemia,
> 17 mmol/L
AUROC 0.68 0.67 0.64 0.64 0.71 0.75 0.64
(95%CI) (0.52-0.80) (0.52-0.81) (0.48-0.78) (0.47-0.78) (0.56-0.86) (0.58-0.90) (0.49-0.77)
Sensitivity 75.00% 66.60% 58.30% 63.60% 66.70% 70.00% 66.70%
Specificity 60.60% 66.60% 68.90% 63.60% 75.00% 79.00% 60.80%
PPV 14.80% 15.40% 14.60% 14.00% 19.50% 21.20% 13.60%
NPV 96.40% 95.70% 94.80% 94.90% 96.10% 97.00% 84.90%
Continuous variable APRI APRI-r1 Mayo risk score MELD score CP score
AUROC 0.68 0.77 0.7 0.63 0.62
(95%CI) (0.49-0.87) (0.64-0.88) (0.54-0.84) (0.43-0.79) (0.47-0.76)
Sensitivity - - - - -
Specificity - - - - -
PPV - - - - -
NPV - - - - -
APRI: AST to platelet ratio index at baseline; APRI-r1: APRI at 1-year; AUROC: Area under receiver operating curve; CP: Child-Pugh; MELD: Model for 
end-stage liver disease; NPV: Negative predictive value; PPV: Positive predictive value.
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effective will be of significant clinical importance in the 
management of PBC patients. 
Our study showed that APRI correlated with adverse 
liver function (in terms of both laboratory parameters 
and also traditional PBC prognostic models - Mayo 
risk score and CP score). In addition, a higher APRI-r1 
level was associated with a higher HCC risk. Although 
being regarded as a fibrosis/cirrhosis marker, APRI-r1 
retained the association with HCC development despite 
the inclusion of cirrhosis into the multivariate analysis 
(adjusted HR = 3.94). This is likely because APRI 
has an additional role of reflecting other pathological 
pathways including liver inflammation and non-
cirrhotic portal hypertension[26-28].
Suboptimal treatment response was not an 
independent risk factor, in contrary to that reported 
by Trivedi et al[10]. There are a few possible reasons 
to account for this. First, as disease stage is known 
to affect the treatment response[11,12], the effect of 
treatment response on HCC risk would be attenuated 
by including APRI and cirrhosis into the multivariate 
analysis. Second, our study might not be adequately 
powered to detect this effect given the limited number 
of events. However, by combining both factors (APRI-r1 
and treatment response), the HCC risk of individuals 
could be further stratified into low-risk, intermediate-
risk and high-risk. 
Hyperbilirubinemia was recognized to be a risk 
factor for liver transplantation and death in PBC patients 
in previous studies[37,40,41], but was not a significant 
independent risk factor for HCC development in the 
current study. This is likely related to the fact that 
hyperbilirubinemia in patients with PBC can also be 
due to cholestasis, while APRI is more specifically 
related to fibrosis/cirrhosis. 
Our study also determined the predictive per-
formances of APRI and APRI-r1 in addition to the 
traditional prognostic models and treatment response 
criteria. We showed that APRI-r1 had a satisfactory 
performance, with an AUROC of 0.77. It appears 
that APRI-r1 outperformed other prognostic models, 
although the result should be interpreted with caution 
as there was overlapping of the 95%CIs of some 
models (e.g., Mayo risk score) due to the relatively 
small sample size of our cohort. 
Cases were identified by searching the electronic 
database system of the hospital with subsequent review 
of the clinical records. This ensures the accurate and 
complete capture of all PBC cases. Another noticeable 
strength of the study is the long follow-up duration (up 
to 26 years), since a long lag time is usually required 
from PBC diagnosis to HCC development. Moreover, 
the inclusion of a homogenous group of Chinese 
patients and exclusion of concomitant liver diseases 
removed the confounding factors of ethnicity and 
hepatitis due to other liver diseases.
A few limitations are present in the current study. 
First, a relatively small sample size may render the 
study underpowered to confirm a significant association 
of some factors with HCC development (e.g., smoking 
and alcohol), although previous study also failed to 
show an association with these factors[42]. Second, 
since this study was carried out in a tertiary center, 
selection bias may account for the higher HCC 
incidence rate in our cohort (10.6 cases per 1000 
person-years). On the contrary, the study by Trivedi et 
al[10], which was a multi-center study involving 4565 
patients, reported an incidence rate of only 3.4 cases 
per 1000 person-years. Third, our study recruited only 
Asian subjects, and therefore the applicability of this 
finding to other ethnicities remains to be investigated. 
Fourth, as this is only a single-center study with a 
relatively small sample size, validation studies from 
other centers are necessary. Lastly, while APRI was 
shown to be of both predictive and prognostic values 
in chronic viral hepatitis patients[23-25], studies on the 
usefulness of this marker in other chronic liver diseases 
are still lacking. Consistent findings are expected 
as fibrosis/cirrhosis is the major risk factor for HCC 
development, although further studies on other chronic 
liver diseases are warranted. 
In conclusion, our study confirmed the usefulness 
of APRI-r1 in predicting HCC development in PBC 
patients receiving UDCA. The combination of APRI-r1 
with treatment response allowed further stratification 
of HCC risk. Owing to its non-invasiveness and 
cost-effectiveness, APRI can be used as a marker 
to streamline the HCC surveillance protocol in PBC 
patients. 
ARTICLE HIGHLIGHTS
Research background
No reliable predictive models exist for hepatocellular carcinoma (HCC) in 
primary biliary cholangitis (PBC). Aspartate aminotransferase (AST) to platelet 
ratio index (APRI) not only captures fibrosis/cirrhosis, but also reflects other 
biologically significant pathways like hepatic necroinflammation or non-cirrhotic 
portal hypertension. The usefulness of APRI in predicting HCC in PBC remains 
unknown. 
Research motivation
A predictive marker for HCC development in PBC patients will help disease 
prognostication and streamline the follow-up and HCC surveillance strategy. 
Research objectives
To investigate the usefulness of APRI in predicting HCC in PBC. 
Research methods
The authors recruited all PBC patients who had follow-up in the Hepatology 
Clinic of Queen Mary Hospital (QMH) between January 2000 and October 
2015. Patients were followed up every 3 to 6 mo with regular monitoring of 
platelet count, liver biochemistry, prothrombin time and alpha-fetoprotein level. 
In the analysis of the risk factors for adverse events, suboptimal response to 
UDCA was identified by using various treatment response criteria. APRI-r1 
in combination with treatment response criteria enables further stratification 
of PBC patients into low-risk (biochemical response with APRI-r1 ≤ 0.54), 
intermediate-risk (suboptimal biochemical response with APRI-r1 ≤ 0.54, 
or biochemical response with APRI-r1 > 0.54) and high-risk (suboptimal 
biochemical response with APRI-r1 > 0.54) groups of developing adverse 
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outcomes in terms of liver transplantation or death. The Cox proportional 
hazards model was used to determine the hazard ratio (HR) of HCC with 
different variables. The Kaplan-Meier method was used to analyze the 
development of HCC. The performances of various prognostic models were 
expressed in terms of area under the receiver operating curve (AUROC). 
Research results
A total of 144 patients were identified. The median age at diagnosis was 57.8 
years (interquartile range: 48.7-71.5 years), and 41 (28.5%) had baseline 
cirrhosis. The median follow-up duration was 6.9 years (range: 1.0-26.3 
years), with a total of 1136 patient-years. Twelve patients developed HCC, with 
an incidence rate of 10.6 cases per 1000 patient-years. The overall 5-, 10- 
and 15-year probabilities of HCC development were 2.3% [95% confidence 
interval (CI): 0%-4.8%], 8.4% (95%CI: 1.8%-14.5%) and 21.6% (6.8%-34.1%), 
respectively. Independent risk factors for HCC development were older age (HR 
= 1.07), cirrhosis (HR = 4.38) and APRI at 1 year after treatment (APRI-r1) > 0.54 
(HR = 3.94). APRI-r1 in combination with treatment response further stratified 
the risk of HCC development (log rank p < 0.05). The AUROC of APRI-r1 in 
predicting HCC was 0.77 (95%CI: 0.64-0.88). 
Research conclusions
APRI-r1 can be used as a predictive marker for HCC development in PBC 
patients. Combination of APRI-r1 with treatment response can further stratify 
the HCC risk.
Research perspectives
Our study confirmed the usefulness of APRI-r1 in predicting 
HCC development in PBC patients receiving UDCA. The 
combination of APRI-r1 with treatment response allowed further 
stratification of HCC risk. Owing to its non-invasiveness and cost-
effectiveness, APRI can be used as a marker to streamline the 
HCC surveillance protocol in PBC patients. Future multi-center 
studies with larger sample size are warranted to confirm our 
findings.
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